IGFBP1 and prostate carcinoma: Higher BMI is associated with lower concentrations of IGFBP-1 and IGFBP-2 [45], which might lead to higher bioavailability of IGF-I, but evidence on the association of these binding proteins with prostate cancer mortality is very limited.